Therefore, expression of DR5 induced by PGA2 via p53 and CHOP in cancer cells containing wild-type p53 and mutant p53, respectively, may have the potential to enhance the anti-cancer therapeutic effect of TRAIL. The gene discussed is TP53; the disease is cancer.